Draft -conceptual Modeling: a Report of the Ispor-smdm Modeling Good Research Practices Task Force Working Group -part 2

Department of Health Policy and Management University of Pittsburgh Graduate School of Public Health, USA Department of Medicine, University of Pittsburgh School of Medicine, USA Institute for Health, Rutgers University, USA Yale University, New Haven, CT, USA GlaxoSmithKline, United Kingdom Health Economics & Outcomes Research Ltd, Monmouth, Wales Toronto Health Economics and Technology Assessment Collaborative, University of Toronto, Toronto, CAN

[1]  A. Mulley,et al.  Management of acute dysuria. A decision-analysis model of alternative strategies. , 1985, Annals of internal medicine.

[2]  L. Goldman,et al.  Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. , 1987, American journal of public health.

[3]  A. Sonnenberg,et al.  Efficient management of diarrhea in the acquired immunodeficiency syndrome (AIDS). A medical decision analysis. , 1990, Annals of internal medicine.

[4]  W. Leslie,et al.  The dynamics of HIV spread: a computer simulation model. , 1990, Computers and biomedical research, an international journal.

[5]  Harlan M. Krumholz,et al.  Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. , 1992, The New England journal of medicine.

[6]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[7]  R. Shavelson,et al.  Problems and Issues in the Use of Concept Maps in Science Assessment. , 1996 .

[8]  D K Owens,et al.  Use of Influence Diagrams to Structure Medical Decisions , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[9]  A S Detsky,et al.  Primer on Medical Decision Analysis: Part 2—Building a Tree , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[10]  Giovanni Parmigiani,et al.  The Stroke Prevention Policy Model: Linking Evidence and Clinical Decisions , 1997, Annals of Internal Medicine.

[11]  Ross D. Shachter,et al.  Representation and Analysis of Medical Decision Problems with Influence Diagrams , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[12]  A S Detsky,et al.  Primer on Medical Decision Analysis: Part 1—Getting Started , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[13]  M C Weinstein,et al.  The cost-effectiveness of preventing AIDS-related opportunistic infections. , 1998, JAMA.

[14]  M L Brandeau,et al.  HIV transmission and the cost-effectiveness of methadone maintenance. , 2000, American journal of public health.

[15]  M C Weinstein,et al.  The cost effectiveness of combination antiretroviral therapy for HIV disease. , 2001, The New England journal of medicine.

[16]  S. Blower,et al.  Amplification Dynamics: Predicting the Effect of HIV on Tuberculosis Outbreaks , 2001, Journal of acquired immune deficiency syndromes.

[17]  G. Samsa,et al.  Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. , 2002, The American journal of medicine.

[18]  G. Chapman,et al.  Decision Making in Health Care: Theory, Psychology, and Applications , 2003 .

[19]  David M Eddy,et al.  Archimedes: a trial-validated model of diabetes. , 2003, Diabetes care.

[20]  A simulation to assess the conditions required for high level heterosexual transmission of HIV in Africa , 2004, International journal of STD & AIDS.

[21]  Stirling Bryan,et al.  Modelling in the economic evaluation of health care: selecting the appropriate approach , 2004, Journal of health services research & policy.

[22]  G. Clermont,et al.  In silico design of clinical trials: A method coming of age , 2004, Critical care medicine.

[23]  M Sculpher,et al.  Review of guidelines for good practice in decision-analytic modelling in health technology assessment. , 2004, Health technology assessment.

[24]  Anke Richter,et al.  Health and Economic Impacts of an HIV Intervention in Out of Treatment Substance Abusers: Evidence from a Dynamic Model , 2005, Health care management science.

[25]  Steven M. Shechter,et al.  Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation. , 2006, The Journal of antimicrobial chemotherapy.

[26]  M. Kozal,et al.  Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies , 2007, AIDS.

[27]  A. Miners,et al.  Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups , 2007, International Journal of Technology Assessment in Health Care.

[28]  Mark S Roberts,et al.  Estimating the rate of accumulating drug resistance mutations in the HIV genome. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[29]  Gilles Clermont,et al.  Equation-based models of dynamic biological systems. , 2008, Journal of critical care.

[30]  Gilles Clermont,et al.  A MATHEMATICAL SIMULATION OF THE INFLAMMATORY RESPONSE TO ANTHRAX INFECTION , 2008, Shock.

[31]  Andrew Schaefer,et al.  Influence of Alternative Thresholds for Initiating HIV Treatment on Quality-Adjusted Life Expectancy: A Decision Model , 2008, Annals of Internal Medicine.

[32]  Michael Drummond,et al.  Moving the QALY forward: rationale for change. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[33]  M. Drummond,et al.  Toward a consensus on the QALY. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[34]  L. Garrison.  Editorial: On the benefits of modeling using QALYs for societal resource allocation: the model is the message. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[35]  Daniel Kahneman,et al.  A different approach to health state valuation. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[36]  Erik Buskens,et al.  A tutorial on discrete-event simulation for health policy design and decision making: optimizing pediatric ultrasound screening for hip dysplasia as an illustration. , 2009, Health policy.

[37]  M. Weinstein,et al.  QALYs: the basics. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[38]  Peter J Neumann,et al.  Costing and Perspective in Published Cost-Effectiveness Analysis , 2009, Medical care.

[39]  P. Kind,et al.  The use of QALYs in clinical and patient decision-making: issues and prospects. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[40]  Benjamin P. Linas,et al.  Improving Outcomes in State AIDS Drug Assistance Programs , 2009, Journal of acquired immune deficiency syndromes.

[41]  Douglas K Owens,et al.  Potential population health outcomes and expenditures of HIV vaccination strategies in the United States. , 2009, Vaccine.

[42]  Przemyslaw Perlikowski,et al.  Understanding Coin-Tossing , 2010 .

[43]  Eric J Feuer,et al.  Dynamic Microsimulation Models for Health Outcomes , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

[44]  James E. Stahl,et al.  Pharmacoeconomics 2008; 26 (2): 131-148 , 2012 .

[45]  L. Cipriano,et al.  Guidelines for the Economic Evaluation of Health Technologies: Canada , 2012 .

[46]  David Henry,et al.  Economic Analysis as an Aid to Subsidisation Decisions , 2012, PharmacoEconomics.